株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アレルギー性結膜炎 : パイプライン製品の分析

Allergic Conjunctivitis - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 192452
出版日 ページ情報 英文 70 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.38円で換算しております。
Back to Top
アレルギー性結膜炎 : パイプライン製品の分析 Allergic Conjunctivitis - Pipeline Review, H2 2017
出版日: 2017年10月31日 ページ情報: 英文 70 Pages
概要

アレルギー性結膜炎は、まぶたの裏および白目(結膜)を覆う組織の透明層が、花粉、ふけ、かび、またはその他のアレルギー原因物質によって腫れるまたは炎症を起こす時に発症します。症状には、激しいかゆみ、眼瞼浮腫、白目を覆う透明細胞層の血管拡大(拡張)および粘々とした眼脂が含まれます。治療には抗ヒスタミン剤または抗炎症薬療法が用いられます。

当レポートでは、世界におけるアレルギー性結膜炎治療薬のパイプライン製品について取り上げ、現在の開発パイプラインの状況や最新動向、後期段階および中止されたプロジェクトの情報、主要企業および彼らが開発中の製品のレビューなどをお届けします。

イントロダクション

  • 調査範囲

アレルギー性結膜炎 - 概要

アレルギー性結膜炎 - 治療薬の開発

  • パイプラインの概要
  • 企業別のパイプライン動向
  • 企業で開発中の製品

アレルギー性結膜炎 - 治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

アレルギー性結膜炎の治療薬開発に従事している企業

薬剤プロファイル

アレルギー性結膜炎 - 休止中のプロジェクト

アレルギー性結膜炎 - 開発が中止された製品

アレルギー性結膜炎 - 製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9837IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Allergic Conjunctivitis - Pipeline Review, H2 2017, provides an overview of the Allergic Conjunctivitis (Ophthalmology) pipeline landscape.

Allergic conjunctivitis occurs when the clear layer of tissue lining the eyelids and covering the white of the eye (conjunctiva) become swollen or inflamed due to a reaction to pollen, dander, mold, or other allergy-causing substances. Symptoms include intense itching, puffy eyelids, widened (dilated) vessels in the clear tissue covering the white of the eye and stringy eye discharge. Treatment includes antihistamine or anti-inflammatory medication.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Allergic Conjunctivitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 3, 8 and 1 respectively.

Allergic Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Allergic Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Allergic Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Allergic Conjunctivitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Allergic Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Allergic Conjunctivitis - Overview
    • Allergic Conjunctivitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Allergic Conjunctivitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Allergic Conjunctivitis - Companies Involved in Therapeutics Development
    • Accolade Pharmaceuticals LLC
    • Aldeyra Therapeutics Inc
    • AlleCures Inc
    • Allergan Plc
    • Clevexel Pharma SAS
    • Griffin Discoveries BV
    • Ocular Therapeutix Inc
    • Ohr Pharmaceutical Inc
    • Portola Pharmaceuticals Inc
    • Re-Pharm Ltd
    • Realm Therapeutics Plc
    • Sylentis SAU
    • Xencor Inc
  • Allergic Conjunctivitis - Drug Profiles
    • ADX-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AGN-229666 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Allergic Conjunctivitis and Allergic Rhinitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CPC-888 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CVXL-0074 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dexamethasone acetate SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Allergic Conjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GD-134 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GD-136 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PR-013 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRT-2761 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RP-0217 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-266 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SYL-116011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XmAb-7195 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Zafi-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Allergic Conjunctivitis - Dormant Projects
  • Allergic Conjunctivitis - Discontinued Products
  • Allergic Conjunctivitis - Product Development Milestones
    • Featured News & Press Releases
      • Oct 16, 2017: Realm Therapeutics to Present Update on Drug Development Program PR013 at 2017 BIO Investor Forum
      • Oct 10, 2017: Aldeyra Therapeutics Announces New Data on ADX-102 at 2017 Research & Development Day
      • Sep 27, 2017: Aldeyra Therapeutics Announces 2017 Research and Development Day
      • Sep 21, 2017: Realm Therapeutics Provides Clinical Development Update on PR013
      • Sep 11, 2017: Realm Therapeutics - FDA Permits PR013 to Proceed to Phase II Trial
      • Sep 07, 2017: Realm Therapeutics to present update on PR013 at the Rodman & Renshaw 19th Annual Global Investment Conference
      • Aug 02, 2017: Realm Therapeutics Submits Investigational New Drug Application for PR013 for Allergic Conjunctivitis
      • Jul 06, 2017: Realm Therapeutics - Presentation at World Congress on Inflammation
      • Jun 14, 2017: Aldeyra Therapeutics Announces Results from Allergic Conjunctivitis Phase 2b Clinical Trial and Plans for Phase 3 Clinical Testing
      • Jun 14, 2017: Realm Therapeutics to present on PR013 at the 2017 Marcum Microcap Conference
      • Jun 13, 2017: Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Results from Allergic Conjunctivitis Phase 2b Clinical Trial
      • Apr 18, 2017: Aldeyra Therapeutics Announces Last Patient Dosed in Allergic Conjunctivitis Phase 2b Clinical Trial
      • Feb 07, 2017: Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 2b Clinical Trial
      • Jan 05, 2017: Realm Therapeutics to provide update on PR013 at the 2017 Dermatology Summit and Biotech Showcase
      • Dec 05, 2016: Noveome Initiates Phase 2 Clinical Trial of ST266 for the Treatment of Allergic Conjunctivitis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Allergic Conjunctivitis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Allergic Conjunctivitis - Pipeline by Accolade Pharmaceuticals LLC, H2 2017
  • Allergic Conjunctivitis - Pipeline by Aldeyra Therapeutics Inc, H2 2017
  • Allergic Conjunctivitis - Pipeline by AlleCures Inc, H2 2017
  • Allergic Conjunctivitis - Pipeline by Allergan Plc, H2 2017
  • Allergic Conjunctivitis - Pipeline by Clevexel Pharma SAS, H2 2017
  • Allergic Conjunctivitis - Pipeline by Griffin Discoveries BV, H2 2017
  • Allergic Conjunctivitis - Pipeline by Ocular Therapeutix Inc, H2 2017
  • Allergic Conjunctivitis - Pipeline by Ohr Pharmaceutical Inc, H2 2017
  • Allergic Conjunctivitis - Pipeline by Portola Pharmaceuticals Inc, H2 2017
  • Allergic Conjunctivitis - Pipeline by Re-Pharm Ltd, H2 2017
  • Allergic Conjunctivitis - Pipeline by Realm Therapeutics Plc, H2 2017
  • Allergic Conjunctivitis - Pipeline by Sylentis SAU, H2 2017
  • Allergic Conjunctivitis - Pipeline by Xencor Inc, H2 2017
  • Allergic Conjunctivitis - Dormant Projects, H2 2017
  • Allergic Conjunctivitis - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Allergic Conjunctivitis - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Allergic Conjunctivitis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top